Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-04-07
2004-09-14
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S331000
Reexamination Certificate
active
06790852
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to new 2-(2,6-dichlorophenyl)-diarylimidazoles and their pharmaceutically acceptable salts. These compounds are protein-tyrosine kinase inhibitors, especially inhibitors of c-met kinase and are therefore excellent therapeutics for the treatment of cancer. The invention relates also to pharmaceutical compositions that contain these new compounds as active agents for the treatment of cancer and cancer related diseases.
BACKGROUND OF THE INVENTION
Protein-tyrosine kinases (PTKs), enzymes that catalyse the transfer of the &ggr;-phosphate of ATP to tyrosine residues of protein substrates, are critical components of signalling pathways that control cellular proliferation and differentiation. PTKs are subdivided into two large families, receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (NRTKs). RTKs span the plasma membrane and contain an extra-cellular domain, which binds ligand, and an intracellular portion, which possesses catalytic activity and regulatory sequences. Most RTKs, like the hepatocyte growth factor receptor c-met, possess a single polypeptide chain and are monomeric in the absence of ligand. Ligand binding to the extracellular portion of RTKs, dimerizes monomeric receptors, resulting in autophosphorylation of specific tyrosine residues in the cytoplasmic portion (for review see: Blume-Jensen, P., and Hunter, T., Nature 411 (2001) 355-365; Hubbard, S. R., et al., J. Biol. Chem. 273 (1998) 11987-11990; Zwick, E., et al., Trends Mol. Med. 8 (2002) 17-23). In general, tyrosine autophosphorylation either stimulates the intrinsic catalytic kinase activity of the receptor or generates recruitment sites for downstream signalling proteins containing phosphotyrosine-recognition domains, such as the Src homology 2 (SH2) domain or the phosphotyrosine-binding (PTB) domain.
Protein tyrosine kinases play a critical role in intracellular signal transduction pathways leading to diverse cellular responses such as proliferation, apoptosis and differentiation. Consequently, these enzymes have become primary targets for the development of novel therapeutics designed to block cancer cell proliferation, metastasis, angiogenesis and promote apoptosis. The strategy that has progressed farthest in clinical development is the use of monoclonal antibodies to target growth factor receptor tyrosine kinases. The use of small molecule tyrosine kinase inhibitors however could have significant theoretical advantages over monoclonal antibodies. Small molecule inhibitors could have better tissue penetration, could have activity against intracellular targets and mutated targets and could be designed to have oral bioavailability. Several lead compounds have shown promising activity against such targets as the EGFR, the vascular endothelial cell growth factor receptor and bcr-abl.
The hepatocyte growth factor receptor c-met was first identified as an activated oncogene in an N-methyl-N′-nitrosoguanidinic treated human osteogenic sarcoma cell line (MUNG-HOS) by its ability to transform NIH 3T3 mouse fibroblasts. The receptor encoded by the c-met protooncogene (located on chromosome 7) is a two-chain protein composed of 50 kDa(&agr;) chain disulfide linked to a 145 kDa(&bgr;) chain in an &agr;&bgr; complex of 190 kDa. The &agr; chain is exposed at the cell surface while the &bgr; chain spans the cell membrane and possesses an intracellular tyrosine kinase domain. The presence of this intracellular tyrosine kinase domain groups c-met as a member of the receptor tyrosine kinase (RTK) family of cell surface molecules.
Hepatocyte growth factor (HGF), also known as Scatter Factor (SF), is a multifunctional cytokine that elicits diverse responses in different cells and tissues. Since its initial discovery and characterisation HGF/SF has been the subject of intense research, particularly regarding its role in cancer development and progression. Much evidence now points to its role as a regulator of carcinogenesis, cancer invasion and metastasis (for review see: Herynk, M. H., and Radinsky, R., In Vivo 14 (2000) 587-596; Jiang, W., et al., Crit. Rev. Oncol. Hematol. 29 (1999) 209-248; Longati, P., et al., Curr. Drug Targets 2 (2001) 41-55; Maulik, G., et al., CytokineGrowth Factor Rev. 13 (2002) 41-59; Parr, C., and Jiang, W. G., Histol. Histopathol. 16 (2001) 251-268.
HGF/SF binds to and induces tyrosine phosphorylation of the mature c-met receptor &bgr; chain. Such events are thought to promote binding of intracellular signalling proteins containing src homology (SH) regions such as PLC-&ggr;, Ras-GAP, PI-3 kinase pp60
c-src
and the GRB-2 Socs complex to the activated receptor. Each SH2-containing protein may activate a different subset of signalling phosphopeptides, thus eliciting different responses within the cell.
C-met mutations have been well-described in hereditary and sporadic human papillary renal carcinomas and have been reported in ovarian cancer, childhood hepatocellular carcinoma, metastatic head and neck squamous cell carcinomas, and gastric cancer. C-met is also over-expressed in both non-small cell lung cancer and small cell lung cancer cells, in breast, colon and prostate tumors. Since c-met appears to play an important role in oncogenesis of a variety of tumors, various inhibition strategies have been employed to therapeutically target this receptor tyrosine kinase.
The usefulness of inhibiting the protein-tyrosine kinase c-met for inhibiting tumor growth and invasion has been shown in many well documented preclinical experiments (e.g., Abounader, R., et al., J. Natl. Cancer Inst. 91 (1999) 1548-1556; Laterra, J., et al., Lab. Invest. 76 (1997) 565-577; Tomioka, D., Cancer Res. 61 (2001) 7518-7524; Wang, R., et al., J. Cell Biology 153 (2001) 1023-1033).
WO 96/18626 discloses inhibitors of tyrosine kinases and c-met kinase which are derivatives of 2-(2,6-dichlorophenyl)-4-phenyl-5-(pyridin-4yl)-1H-imidazole (examples 5, 6 and 55). However, they show unfavorable cytochrome P450 interactions and also some undesirable physical properties like low bioavailability.
It has now been found, that the 2-(2,6-dichlorophenyl)-4-phenyl-5-(pyrimidin-4yl)-1H-imidazoles according to this invention avoid these disadvantages and show improved properties as protein-tyrosine kinase inhibitors.
It is, therefore, desirable to have a compounds that avoid the above-described disadvantageous and show improved properties as protein-tyrosine kinase inhibitors.
SUMMARY OF THE INVENTION
It was surprisingly found that the pharmaceutical and anti-tumorigenic activities, due to the c-met inhibition of the compounds according to this invention are especially provided by the presence of a 2,6-dichlorophenyl residue in 2-position of the imidazole ring.
The invention relates to compounds of formula (I)
wherein
X is hydrogen; OR
1
; SR
2
; (SO)R
2
; (SO
2
)R
2
; or a group A
1
—Q;
A
1
represents a C
1
-C
3
-alkylen group;
Q is OR
1
; SR
2
; SOR
2
; SO
2
R
2
; NR
3
R
4
; NHCH
2
CH
2
NR
3
R
4
or halogen;
R
1
is selected from the group consisting of hydrogen; C
1
-C
3
-alkyl; allyl; dimethylphosphonylmethyl; 2,3-epoxy-1-propyl; (R)-2,3-dihydroxy-1-propyl; (S)-2,3-dihydroxy-1-propyl; 1,3-dihydroxy-2-propyl; 3-hydroxy-2-hydroxymethyl-1-propyl; 2-methoxyethoxymethyl; 2,2-dimethyl-1,3-dioxolan-4-ylmethyl or a group A
1
—Q
1
;
Q
1
represents C
1
-C
2
-alkoxy; cyano; carboxyl; C
1
-C
6
-alkoxycarbonyl; carboxamide; —CO—NR
3
R
4
; C
1
-C
6
-alkylsulfanyl; C
1
-C
6
-alkylsulfenyl; C
1
-C
6
-alkylsulfonyl and in case that A
1
represents an 1,2-ethylen- or 1,3-propylen group, Q
1
is hydroxy or NR
3
R
4
;
R
2
is C
1
-C
6
-alkyl; dimethylphosphonylmethyl; 2,3-epoxy-1-propyl; 2,3-dihydroxy-1-propyl; 2,2-dimethyl-1,3-dioxolan-4-ylmethyl or A
1
—Q
1
;
R
3
and R
4
are independently selected from the group consisting of hydrogen; C
1
-C
6
-alkyl or together form a 5 to 7 membered, saturated or unsaturated ring, optionally substituted by a methyl group and containing one or two heteroatoms, independently selected from N or O;
Y is hydrogen or a group A
2
—R;
A
2
is unsubst
Brandt Michael
Fertig Georg
Krell Hans-Willi
von Hirschheydt Thomas
Voss Edgar
Hoffmann-La Roche Inc.
Johnston George W.
Raymond Richard L.
Rocha-Tramaloni Patricia S.
LandOfFree
2-(2,6-dichlorophenyl)-diarylimidazoles does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-(2,6-dichlorophenyl)-diarylimidazoles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-(2,6-dichlorophenyl)-diarylimidazoles will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3210407